Immune Infiltration and Prostate Cancer. by Strasner, Amy & Karin, Michael
UC San Diego
UC San Diego Previously Published Works
Title
Immune Infiltration and Prostate Cancer.
Permalink
https://escholarship.org/uc/item/13x72463
Journal
Frontiers in oncology, 5(MAY)
ISSN
2234-943X
Authors
Strasner, Amy
Karin, Michael
Publication Date
2015
DOI
10.3389/fonc.2015.00128
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
MINI REVIEW
published: 08 July 2015
doi: 10.3389/fonc.2015.00128
Edited by:
Shidong Jia,
Genentech Inc, USA
Reviewed by:
Rosemary O’Connor,
University College Cork, Ireland
Claire Perks,
University of Bristol, UK
*Correspondence:
Michael Karin,
Laboratory of Gene Regulation and
Signal Transduction, Departments of
Pharmacology and Pathology,
University of California San Diego
School of Medicine, 9500 Gilman
Drive Mail Code 0723, La Jolla,
CA 92093, USA
karinoffice@ucsd.edu
Specialty section:
This article was submitted to Cancer
Endocrinology, a section of the journal
Frontiers in Oncology
Received: 02 April 2015
Accepted: 22 May 2015
Published: 08 July 2015
Citation:
Strasner A and Karin M (2015)
Immune infiltration and prostate
cancer.
Front. Oncol. 5:128.
doi: 10.3389/fonc.2015.00128
Immune infiltration and prostate
cancer
Amy Strasner 1,2 and Michael Karin1,2*
1 Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California San Diego
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It is becoming increasingly clear that inflammation influences prostate cancer (PCa)
development and that immune cells are among the primary drivers of this effect. This
information has launched numerous clinical trials testing immunotherapy drugs in PCa
patients. The results of these studies are promising but have yet to generate a complete
response. Importantly, the precise immune profile that determines clinical outcome
remains unresolved. Individual immune cell types are divided into various functional
subsets whose effects on tumor development may differ depending on their particular
phenotype and functional status, which is often shaped by the tumor microenvironment.
Thus, this review aims to examine the current knowledge regarding the role of inflamma-
tion and specific immune cell types in mediating PCa progression to assist in directing
and optimizing immunotherapy targets, regimens, and responses and to uncover areas
in which further research is needed. Finally, a summary of ongoing immunotherapy clinical
trials in PCa is provided.
Keywords: prostate cancer, immune cells, inflammation, immunotherapy, B cells
Introduction
Prostate cancer (PCa) is themost common non-cutaneous cancer and second leading cancer-related
cause of death of men in the United States. (1). Localized PCa can be controlled with surgery or
radiation over 80% of the time. If prostate tumors are metastatic at presentation, neither surgery
nor radiation will confer significant clinical benefit and androgen deprivation therapy (ADT)
represents the sole therapeutic option for such patients. Unfortunately, resistance to hormonal
targeting develops in most patients within 2 years, a state that is termed metastatic castration-
resistant PCa (mCRPC) and is virtually untreatable (2, 3). Until recently, Docetaxel was the lone
accepted remedy for mCRPC and was associated with a 2- to 3-month enhancement of survival (4–
6). The advent of newer chemotherapeutic agents such as cabazitaxel and approval of next generation
drugs abiraterone and enzalutamide have improved upon this effect (7–10), yet resistance ultimately
ensues, possibly via mutations in the androgen receptor (AR) gene (11).
Relative to other forms of cancer, the discovery of valuable predictive markers of disease pro-
gression has been particularly challenging for PCa. Genetic markers capable of identifying clinically
aggressive disease remain elusive (12, 13). In addition, PCa is unique among solid tumors in that
imaging techniques are insufficient for definitive identification and diagnosis of malignancy (12,
14). Instead, the pre-biopsy serum prostate specific antigen (PSA) value is used as an indicator of
potential underlying disease, but the utility of this screening method has been intensely scrutinized
(15). In fact, the United States Preventative Services Task Force (USPSTF) recently recommended
against routine PSA screening (16). Importantly, the ramifications of this ruling may be an increase
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in the proportion of men diagnosed at later stages of PCa (17).
Thus, the identification of novel therapeutic targets for and
biomarkers of mCRPC is severely needed.
A multitude of studies investigating alternative PCa treatment
interventions or predictive markers have focused on components
of the inflammatory response, with promising results. A rela-
tionship between inflammation and cancer was first proposed
by Virchow in 1863 (18) and chronic inflammation is now well
accepted as a driving force behind many malignancies, such as
gastric, colon, esophageal and lung cancers, and hepatocellular
carcinoma (19). While the role of the immune system in PCa is
less clear, it has been implicated both as a possible etiologic agent
and a tumor promoter. A recent report from the REDUCE study
suggesting that aspirin and/or NSAID use decreased risk of PCa
in men with a negative biopsy supports this notion (20). This
review will explore the evidence regarding immune infiltration as
a potential mediator and indicator of aggressive PCa, as well as a
target for PCa therapeutics. Because this topic has been compre-
hensively evaluated elsewhere (21–26), only recent literature will
be addressed here.
Prostatitis and Prostate Cancer:
The Evidence
As with many other cancers, PCa arises from accumulation of
acquired genetic and epigenetic alterations. Currently, age, eth-
nicity, and family history are the only known risk factors for
development of prostate neoplasia. These genetic traits may par-
tially explain the geographical variance in PCa incidence and
mortality, with rates in Southeast and East Asia being much lower
than those in the United States and Western Europe (22, 27).
By contrast, the elevated rate of PCa observed in Chinese and
Japanese men within one generation of relocation to the West
indicates that environmental factors, particularly lifestyle factors
such as diet, also contribute to the emergence of PCa (28). One
likely link between environmental stimuli and PCa occurrence is
chronic inflammation. Support for this hypothesis comes from
reports of focal atrophic lesions in the prostate containing a rela-
tively high percentage of proliferating epithelial cells and acute or
chronic inflammatory infiltrate. These areas, designated prolifer-
ative inflammatory atrophy (PIA), comprise an extensive portion
of the peripheral zone of the prostate, the primary site where PCa
originates, and have been suggested to be precursors of prostatic
intraepithelial neoplastic (PIN) lesions (22, 24, 29), although one
recent retrospective epidemiological study refuted this concept
(30). Additional evidence comes from a recent meta-analysis
assessing 20 case–control studies conducted between 1990 and
2012 that revealed a significant positive relationship between self-
reported prostatitis and PCa. However, the authors were unable
to demonstrate a causal link between the two due to the absence
of cohort studies in this analysis (31). Numerous other epidemi-
ological investigations have examined the connection between
prostatitis and subsequent PCa risk and while early studies (32–
35) described an elevated risk of malignancy or recurrence due
to presence of inflammation, subsequent studies have produced
conflicting results (29, 30, 36–40). In addition to differences in
study populations and potential selection and other forms of
bias, plausible explanations for these inconsistencies include tissue
sample size and composition, definition and measurement of
inflammation, tissue regions assessed, and categories of prostatitis
examined. In order to obtain amore accurate reflection of the rela-
tionship between prostatitis andPCa, improved standardization of
these measurements, incorporation of asymptomatic inflamma-
tory prostatitis, and a prospective design in future epidemiologi-
cal studies are needed. Importantly, many investigations defined
inflammation with discrete variables, such as present or absent or
severe, moderate ormild rather thanwith a detailed analysis of the
cellular composition and distribution of the infiltrate. Although
this classification system may be obligatory for certain statistical
analyses, it is a major limitation of these investigations and may
be masking true associations that exist. Furthermore, these stud-
ies may benefit from experimental research designed to provide
insight regarding the kinetics, distribution, type, and components
of inflammation that are important for prostate tumorigenesis.
Despite the abundance of data evaluating the connection
between prostatitis andPCa, the sources of prostatic inflammation
have yet to be fully elucidated. Proposed causes can be divided
into three broad categories: (1)microorganism induced, including
E. coli, Propionibacterium acnes, and those associated with urine
reflux and sexually transmitted diseases, (2) non-microorganism
induced, such as uric acid crystals formed during urine reflux,
estrogen, dietary factors, especially heterocyclic amines (HCA)
2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP) gen-
erated from cooking meats at high temperatures (41), obesity, and
physical trauma such as corpora amylacea (23–25, 42–44), and (3)
treatment- or tumor-elicited inflammation (45, 46).
Some of these hypotheses were tested using mouse models.
For example, Shinohara et al. reported that intraurethral inoc-
ulation of mice with a prostatectomy-derived strain of P. acnes
elicited prolonged and lobe-specific severe acute and chronic
inflammation that was associated with increased proliferation
and reduced Nkx3.1 and AR expression. Inflammatory infiltrate
consisted of luminal neutrophils and stromal mononuclear cells
(44). Similar observations were noted in experiments using E.
coli. Introduction of this bacterium into mouse urogenital tracts
provoked a dramatic decline in Nkx3.1 and AR expression and a
corresponding enhancement of proliferation as well as the basal
cell marker p63. These changes were pursuant to an early influx
of neutrophils into prostatic lumen and stroma followed by a
surge in stromal mononuclear cells and later a marked increase
in plasma cells (43). Upregulation of pro-inflammatory genes,
including IL-6 and COX-2, was also detected using a comparable
system (42). The effects of these events on PCa pathogenesis were
examined by combining bacteria CP9-induced prostatitis and a
mouse PCa model and revealed that tissue damage resulting from
acute prostatitis facilitates accumulation of stromal α-smooth
muscle actin-positive myofibroblasts and the conversion of basal
cells into luminal cells, which accelerates PCa progression (47).
Non-bacterial inflammatory stimuli were also evaluated with
respect to PCa development. A novel model of prostatitis involv-
ing ubiquitous overexpression of aromatase (AROM+) in mice
exhibited early and persistent prostatic mast cell infiltration
with subsequent accumulation of neutrophils, T lymphocytes,
and macrophages, as well as increased expression of numerous
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chemokines. This chronic inflammation preceded formation of
PIN lesions containing and surrounded by immune cells (48).
Finally, Birbach et al. expressed a constitutively active form of
the inflammatory mediator IκB kinase 2 in prostate epithelium of
mice harboring a heterozygousPtendeletion anddetected a robust
inflammatory response, primarily encompassing neutrophils and
macrophages in the prostate, that was accompanied by increased
tumor size due to enhanced epithelial and stromal proliferation,
generation of cribiform structures and stromal remodeling, but no
invasion or metastasis (49).
Together, these data corroborate the ability of inflammatory
stimuli to generate an immune response that modulates the local
environment into one that is conducive to malignant transfor-
mation and progression and implicate chronic inflammation as
a causative factor in PCa. More studies combining prostatitis and
murine PCamodels are needed to confirm these effects and deter-
mine the mechanisms by which these agents promote disease. Of
course, these results also must be confirmed in humans.
Immune Cells and Prostate Cancer:
Friends or Foes?
As previously described, epidemiological studies exploring the
relationship between prostatitis and PCa development may be
limited by the absence of characterization of cellular phenotypes
displayed by tumor-infiltrating leukocytes (TIL). However, many
studies assessing the association between specific immune cells
and PCa are now available and those conducted between 2008
and 2014 are summarized according to cell type in Table 1.
Most of these investigated CD3+, CD4+, or CD8+ cells in
prostatectomy or biopsy tissue of PCa patients and found such
cells to be pro-tumorigenic. For example, a cross-sectional study
of lymphocyte infiltration in tumor tissue microarrays from
patients with PSA recurrence reported that extremely high or low
CD3+ cell counts were correlated with reduced PSA recurrence-
free survival (RFS) (50). Importantly, CD3 was the only T-cell
marker included in this study and no evaluations of T-cell subsets
were performed. Thus, the variation in clinical outcomes across
CD3+ cell quartiles may at least partially reflect differences in
T-cell populations. In fact, the authors mentioned unpublished
data indicating that higher numbers of regulatory T-cells (Treg)
were associated with more advanced tumor stage and PSA-RFS.
A likely assumption is that the CD3+ cells whose low numbers
conferred poor prognoses were protective in nature. Thus, it is
critical to determine not only the cell type but also the subtype
associated with different outcomes in order to better direct
therapeutic efforts. By contrast, the spontaneous TRAMP mouse
PCa model was used to illustrate that the trafficking of a naturally
arising clonally expanded PCa histone H4-specific population of
CD44+CD8+ T-cells to prostate tissue lessened tumor burden
but failed to improve survival (51). Several possible explanations
for the lack of survival impact exist. First, it may be that the
anti-tumorigenic CTL were initially successful in eliminating
tumor cells but were eventually rendered inactive by a suppressive
tumor microenvironment. Alternatively, it is conceivable that the
antigen-specific destruction of H4-expressing tumor cells selected
for less immunogenic and possiblymore adeptH4-negative tumor
cells, or instead, that this response exerted pressure on cancer
cells to downregulate MHC or undergo immunoediting of tumor
antigens and thereby escape immune recognition and destruction.
In line with the former hypothesis, several investigations
demonstrated that tumor-infiltrating CTL expressed PD-1, one
of several indicators of T-cell exhaustion, in PCa patients (52, 53).
This is an essential consideration for immunotherapeutic efforts
and emphasizes the importance of evaluating both the cellular
subtype and functional status when assessing TIL.
Another cell type that has received much attention and shown
relatively consistent results in the context of PCa progression is
the tumor-associated macrophage (TAM). All studies analyzed
demonstrated a pro-tumorigenic effect of TAM, although
one report (54) specified that this was true only for M2 type
macrophages. However, only a fraction of the literature displayed
a link between TAM and recurrence (55, 56). In particular,
Nonomura et al. (56) determined TAM count to be a significant
prognostic factor of clinical outcome in PCa patients. A second
study that found TAM to be related to recurrence indicated this
to be true only in the control but not ADT treated group. Thus,
TAM count may be a good biomarker for disease progression,
but further research is needed to identify the specific subset
of macrophages and PCa patients for which this is applicable.
TAM may also represent a viable therapeutic target for PCa, as
demonstrated by Escamilla et al., who showed a reduction in
castration-induced recruitment of pro-tumorigenic TAM and
delayed emergence of CRPC in a mouse Myc-CaP PCa model
following CSF1R inhibition (57).
As expected, presence of immunosuppressive immune cells,
such as Treg (52, 58), myeloid derived suppressor cells (MDSC)
(59–61), and according to one report, TH17 cells (62), in prostate
tissue was suggestive of more aggressive disease, but surprisingly
few studies were able to equate this with clinical prognosis.
Neutrophils and mast cells have also been fairly well studied,
but investigations involving both cell types have generated
conflicting results concerning their influence on PCa. One source
of contention may concern the area of tissue evaluated. This
point is nicely illustrated by Johannson et al. (63), who implicated
peritumoral but not intratumoral mast cells as independent
prognostic variables of PCa progression. In addition, work
from Pittoni et al. (64) emphasized that care must be taken
to evaluate potential negative outcomes when manipulating
immune cell populations with therapies. In the TRAMP model
of murine PCa, targeting mast cells prevented growth of well-
differentiated tumors but simultaneously stimulated progression
of more aggressive, neuroendocrine type tumors. Similarly,
Tang et al. observed a late IL-2-induced expansion of Treg
following castration and immunization that negated the initial
anti-tumorigenic CD8+ T-cell response (65).
Relative to other immune cells, B cells have been gener-
ally overlooked in terms of PCa. However, the importance of
these cells in PCa progression was established in a landmark
and subsequent papers (45, 66, 67) using subcutaneous Myc-
CaP and spontaneous TRAMP mouse PCa models to show
that castration-induced cell death and resulting hypoxia stim-
ulated CXCL13-mediated infiltration of lymphotoxin β (LTb)-
expressing B lymphocytes into regressing tumors. These cells
subsequently activated IKKα, STAT3 and BMI1 in cancer cells to
promote CRPC progression. Notably, interference with any aspect
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TABLE 1 | Immune cells and prostate cancer.
T-cells (CD4+, CD8+, TH17)
Fujii (80) Neutral; no difference in number of CD3+ cells in glandular hyperplasia, PIN, or adenocarcinoma tissues.
Yuan (81) Positive; lymphocyte aggregates found almost exclusively (95.5%) in normal appearing or pre-invasive epithelial structures, many physically
attached to basal cell layers that were often focally disrupted or substantially attenuated. Significantly, fewer aggregates were seen within
invasive tissue. Epithelial cells overlaying immune cells attached to focal disruptions displayed increased stem cell markers, invasive
morphology, and proliferation. CTL was the predominant infiltrating cell type, although mast and NK cells were also present.
Flammiger (50) Positive for high or low CD3+ cell numbers and PSA recurrence-free survival. CD3 T-cells were also higher in ERG positive tumors than ERG
negative tumors. CD3 T-cells were primarily found in stroma and rarely in prostate epithelium.
Valdman (58) Positive for cancer progression; CD4+ and CD8+ cells were increased in cancer vs. non-atrophic benign tissue, but did not correlate with
Gleason Score.
Gannon (55) Positive for elevated CD3+ cells and invasion in control group; ADT increased relative abundance of CD3+ and CD8+ lymphocytes vs. control
group. No correlations with clinical parameters or recurrence were observed in ADT group.
Sfanos (53) N/A: substantial degree of prostate specific CD8+ T-cell clonality in prostate cancer tissue but not peripheral blood; however, PD-1 was
relatively upregulated on CD8+ T-cells infiltrating prostate gland in men with cancer. Clonality was patient-specific.
Ebelt (52) N/A: previously described pronounced clusters of CD3+ cells, predominantly CD4+, formed adjacent to tumor islets. Now report the presence
of PD-1+ and B7-H1+ cells in these clusters and in BPH, but not in carcinoma area or healthy tissues.
Ellem (48) Positive: CD3+ cells increased in the AROM+ mouse model by 40weeks and PIN lesions reminiscent of those in humans developed following
chronic inflammation. A large amount of the inflammatory infiltrate was seen in lumen and stroma surrounding lesions and in lesions themselves.
Sfanos (82) Negative: numerically, most abundant CD4+ cell subset was IFNγ producing TH1 cells. CD4+ prostate infiltrating lymphocytes were skewed
toward either a regulatory T (Foxp3+) or TH17 subtype. TH17 cells showed an inverse correlation with Gleason Score.
Savage (51) Negative: a naturally arising, clonally expanded population of CD8+CD44+ cells that recognize Histone 4 and are prostate cancer specific in
TRAMP mice. These cells traffic to the prostate, proliferate, and reduce tumor burden, but have no effect on overall survival.
B cells
Woo (70) Neutral for clinical parameters, but higher in malignant vs. benign for overall cohort and high risk and recurrent patients.
Fujii (80) Negative; frequency of B cells in benign glands was 59%. This was significantly reduced in PIN and adenocarcinoma.
Flammiger (50) Neutral; number of CD20+ B cells not associated with tumor stage, lymph node status, Gleason Score, preoperative PSA, or PSA
recurrence-free survival.
Ammirante (45) Positive; LTb expressing B cells infiltrate regressing tumors in response to castration-induced cell death and CXCL13 production and mediate
progression to CRPC. Tumor-infiltrating B cells peaked at 1week and receded by 2weeks post-castration.
Gannon (55) Neutral; no change in abundance of CD20+ cells in ADT vs. control group.
Ellem (48) Neutral; no change in CD45R+ B cells in prostate in AROM+ mouse model.
Shalapour et al.
(69)
Positive; Immunosuppressive IgA+ IL-10+PD-L1+ plasmocytes interfere with the immunogenic cell death mediated CTL response to low-dose
oxaliplatin.
Macrophages
Lanciotti (54) Positive for M2 macrophages; 36.6% of patients had higher prevalence of M1 (CD68+) macrophages and 63.4% had higher abundance of M2
(CD163+) macrophages. M1 occurred more frequently in organ confined disease and M2 was associated with more advanced disease. M1:M2
correlated with disease stage while M2 phenotype was related to extracapsular extension. No correlation between M1:M2 ratio and recurrence.
Fujii (80) Positive; CD204+: CD68+ macrophage ratio increased in PIN and adenocarcinoma compared to benign tissue.
Gollapudi (83) Positive for cancer progression; mean CD68+ tumor-associated macrophage (TAM) higher in cancer cores than PIN, which was higher than
benign. Mean TAM higher in Gleason grade 4 than grade 3. No association in mean TAM in cancer cores and age, PSA, or prostate cancer
recurrence following radical prostatectomy.
Nonomura (56) Positive; patients with higher stage or Gleason Score prostate cancer had higher CD68+ TAM counts. Patients with PSA failure had significantly
higher TAM counts than those without. Recurrence-free survival was significantly lower in patients with high TAM counts than those with low
TAM counts. TAM count was determined to be a significant prognostic factor in addition to PSA, Gleason Score, extraprostatic extension,
lymph node metastasis, and distant metastasis.
Gannon (55) Positive; ADT increases the abundance of CD68+ macrophages. This elevated relative abundance of CD68+ cells favored prostate cancer
progression and recurrence in control group. No correlations with clinical parameters or recurrence were observed in the ADT group.
Craig (84) Positive; coinoculation of athymice nude mice with PC3+U937IL-4 or PC3+U937 decreased time to critical tumor mass and increased
angiogenesis and CCL2 expression compared to PC3 alone.
Ellem (48) Positive: F4/80+ cells increased in the AROM+ mouse model by 40 wks and PIN lesions reminiscent of those in humans developed following
chronic inflammation.
Mast cells
Johansson (63) Positive for peritumoral mast cells but negative for intratumoral mast cells: mast cells are independent prognostic variables of prostate cancer
progression, but peritumoral and intratumoral mast cells have differential effects. In animals, mast cells stimulate angiogenic activity and growth
to drive disease progression, possibly via VEGF expression. Peritumoral but not intratumoral mast cells in humans correlated with poor
prognosis. Intratumoral mast cells were negatively associated with metastasis, Gleason score, tumor stage, peritumoral vessel density, and
proliferation and were associated with a good clinical outcome. Mast cells were also recruited to relapsing prostate tumors following castration
therapy in rats.
(Continued)
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TABLE 1 | Continued
Ellem (48) Positive: mast cell numbers significantly increased throughout tissue immediately after puberty and persisted throughout life in the AROM+
mouse model.
Pittoni (64) Positive and negative: mast cells (c-Kit+FcεRI+CD45+CD11b  for FACS and toluidine blue for IHC) increase in prostate tissue upon
progression from PIN to well-differentiated (WD) tumors in response to SCF production, but are absent in poorly differentiated (PD) tumors,
which lack SCF expression. Pharmacological reduction of mast cells suppressed or prevented WD but not PD tumor growth via MMP-9
production. PD exhibited autocrine production of MMP-9. This pattern was recapitulated in human prostate cancer tissue. Paradoxically,
targeting mast cells in TRAMP mice promoted development of aggressive c-Kit+ neuroendocrine tumors.
Fleischman (85) Negative: strong association between high-mast cell (c-Kit+) densities and favorable tumor characteristics in TMA from hormone-naïve patients.
PSA-RFS significantly declined for patients with low-mast cell density and was worst for those who completely lacked mast cells.
Immunosuppressive cells (Tregs, MDSCs)
Valdman (58) Positive for progression but not clinical outcomes: infiltration of Foxp3+ cells was increased in cancer compared to non-atrophic benign tissue
but did not correlate with Gleason score.
Ebelt (52) Positive for progression but not clinical outcomes: Foxp3+ cells were present in previously described clusters of CD4+ lymphocytes adjacent
to tumor cells but were virtually absent in carcinoma area. Collectively, Foxp3+ cells were more frequent in cancer than BPH or healthy tissue,
but were not correlated with Gleason score or TNM.
Garcia (60) Positive: expansion of immunosuppressive (iNOS, arginase) CD11b+Gr1+ MDSC in prostate immediately following Pten deletion in a murine
prostate cancer model. This was particularly apparent at invasive carcinoma stage and was likely due to upregulation of epithelial cell-derived
CSF1 and IL1β.
DiMitri (59) Positive: massive infiltration of Gr1+CD11b+ cells at onset of senescence induced by complete PTEN loss (with or without Docetaxel). These
cells expressed IL1-RA and opposed IL-1α-induced senescence, thereby promoting tumor progression. This phenomenon was also observed
in oncogene-induced tumor models. Human prostate cancer patients whose tumors express high levels of IL1-RA did not respond to Docetaxel
and had shorter DFS.
Idorn (61) Positive: both Docetaxel and untreated patients exhibited high frequencies of myeloid-derived suppressor cells (MDSC)
(HLA-DRlow/negLin CD11b+CD33+) as compared to healthy donors. MDSC iNOS expression and frequency of circulating Treg
(CD3+CD4+CD25hiCD127low) were significantly higher in both groups of prostate cancer patients than healthy controls. MDSC levels were
significantly higher in patients with three negative prognostic factors (elevated LDH, AP, PSA, anemia) vs. 1.
Derhovanessian
(62)
Positive for TH17 cells but not Tregs: prevaccination frequency of IL-17 cells, but not Tregs predicted time to progression in hormone-resistant
prostate cancer patients. Frequency of IL-17+ cells lacking CCR4 expression was indicative of poor prognosis in these individuals.
Neutrophils
Sonpavde (86) Positive: high neutrophil: lymphocyte ratio (NLR) associated with independent poor prognostic impact in post-docetaxel patients with mCRPC.
Fujita (87) Negative: neutrophil count was found to be an independent predictor of prostate cancer in biopsies of Japanese men with elevated PSA levels
or abnormal DRE. An elevated neutrophil count may predict a benign prostate biopsy. A low neutrophil count and elevated PSA level may be
good indicators for biopsy.
Sümbül (88) Neutral: NLR was found to be effective in predicting PSA but not clinical response to docetaxel+prednisone therapy in CRPC patients.
Templeton (89) Positive: NLR>3 was one of a number of variables in a prognostic risk score in men with mCRPC treated with Docetaxel.
Nuhn (90) Positive: mCRPC patients with low pretreatment NLR (3) had significantly longer overall survival than those with high NLR following first-line
Docetaxel therapy.
Shafique (91) Neutral: NLR not associated with survival or risk of death in patients with prostate cancer from Glasgow Inflammation Outcome Study. By
contrast, mGPS, a combination of C-reactive protein and albumin, predicted poorer 5-year overall survival and relative survival independent of
age, socioeconomic status, disease grade, and NLR. Elevated mGPS also had sig. association with excess risk of death among aggressive,
clinically sig. prostate cancer (Gleason 8–10).
Sadeghi (92) Negative: neutropenic [absolute neutrophil count) (ANC) <1.5109/L] African-American patients had significantly higher clinical stages and
pathologic Gleason scores at radical prostatectomy. ANC was sig. predictive of high tumor grade.
of this pathway delayed emergence of hormone-resistant tumors.
These initial findings were extended to reveal that the identi-
cal mechanism operates in androgen-dependent regeneration of
normal prostate progenitor cells (67). Interestingly, an indepen-
dent investigation reported significant reductions in human and
murine PCa tumor growth following combination therapy with
HIF-1α and phospho-STAT3 inhibitors (68). Together, these data
suggest that the B cell response to tissue injury or death following
androgen depletion drives restorative or aberrant proliferation in
the prostate. In addition, a recent report implicates immunosup-
pressive IgA+PD-L1+IL-10+ plasma cells in impeding response to
low-dose chemotherapy in a T-cell-dependent manner (69). The
presence of CD20+ B cells has been documented in human PCa
as well, and the density of these cells was shown to be higher
in malignant than benign tissue (70). Furthermore, a case study
of an advanced PCa patient treated with the B cell depleting
antibody Rituximab produced fairly encouraging results (71). A
Phase 0 clinical trial evaluating Rituximab as neoadjuvant therapy
in patients prior to radical prostatectomy is currently ongoing.
Thus, although research is still in preliminary stages, B cells
may represent an emerging target for PCa immunotherapeutics.
However, it is likely that a damage response (45, 67) and/or an
immunogenic stimulus (69) is needed to make these cells relevant
in prostate carcinogenesis or that only particular subsets, such as
those expressing LTβ, or IgA are crucial.
Prostate Cancer and Immunotherapy
The emergence of immune cells as important mediators of PCa
progression has spawned a multitude of clinical trials targeting
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TABLE 2 | Prostate cancer and immunotherapy.
Therapeutic vaccines Description Response Status
Sipuleucel-T
(Provenge) (72, 77)
Dendritic cell vaccine pulsed
with a chimeric protein
expressing GM-CSF and PAP
as a tumor-associated antigen
Correlation found between
PAP antibody titer and patient
survival, but not with T-cell
proliferative response to
PAP (74)
FDA Approved 2010 for metastatic CRPC patients
Clinical trial showed a relative 22% reduction in risk of death and
4.1-month improvement in median survival as compared with placebo
group. Despite improvement in overall survival (OS), no difference in
progression-free survival (PFS) was observed (72)
Phase II trial with or without radiation in patients with metastatic CRPC
Phase II trial with enzalutamide in patients with metastatic CRPC
Phase II trial with indoximod, an IDO pathway inhibitor for patients with
refractory metastatic disease
Phase II trial with or without pTVG-HP, a DNA-based vaccine expressing
PAP
Studies evaluating combination with ipilimumab (2)
PROSTVAC-VF (93) PSA Antigen+ 3 costimulatory
molecules delivered in viral
vectors
Phase III trial started in 2011 in metastatic CRPC patients
Phase II trial in minimally symptomatic CRPC patients showed no
difference in PFS, but demonstrated an 8.5-month improvement in
median OS and a 44% reduction in risk of death (2, 73)
Phase II study in combination with samarium-153 IV radiation in patients
with CRPC and bone metastasis (2)
Phase II trial in active surveillance patients ongoing
Two Phase II trials in combination with ipilimumab (2)
GVAX (76) Irradiated prostate cancer cell
lines (LNCaP and PC3)
engineered to express GM-CSF
(75, 76)
Only antibody-mediated
responses to vaccine were
detected (74)
Phase III trials terminated for lack of success (2, 74)
Phase I/II trial of GVAX+ hormone therapy
Two Phase III trials in combination with CTLA-4 inhibitor in chemotherapy
naïve and chemotherapy-experienced CRPC patients (74)
PSMA seroreactivity is a potential biomarker for efficacy of
GVAX+ ipilimumab (73)
NCT00583752 Adenovirus/PSA vaccine in
men with recurrent PCa after
local therapy
Pending Phase I trail confirmed safety
Phase II trial in men with accrual almost completed (2)
Protocol: vaccine alone or ADT followed by vaccinations 14 days later
NCT00583024 Adenovirus/PSA vaccine in
men with hormone-refractory
PCa
Pending Phase II trial with accrual completed but results pending
NCT01875250 (94) Enzalutamide alone or in
combination with
PROSTVAC/TRICOM in
non-metastatic hormone
sensitive PCa patients
Pending Phase II study ongoing
DNA-PAP and
DNA-PSA (2)
DNA-based vaccines Two of three patients in
highest dosing group saw
increased PSA doubling time
and increased levels of
PSA-specific IFN-γ-producing
T lymphocytes
Phase I trials demonstrated safety in humans
ProstAtak Adenoviral vector expressing
Herpes virus thymidine kinase
targets tumor cells and is
followed by anti-herpes drug
valacyclovir (Valtrex)
Phase III trial with radiation for patients with localized prostate cancer
Checkpoint inhibitors/
immune modulators
Description Status
Ipilimumab (Yervoy) CTLA-4 checkpoint inhibitor Phase III trial combined with low-dose radiation in late stage mCRPC
patients treated with docetaxel was negative, but showed a trend toward
improved survival (95)
Phase III trial in chemotherapy naïve mCRPC patients (NCT01057810)
has completed accrual but results are not available
Phase II trial following Provenge for patients with chemo-naïve CRPC
Phase II trial plus ADT for patients with incomplete response to ADT
alone for patients with metastatic CRPC
(Continued)
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TABLE 2 | Continued
Checkpoint inhibitors/
immune modulators
Description Status
Phase II trial in combination with hormonal therapy, degarelix, and radical
prostectomy in men with newly diagnosed metastatic castration sensitive
disease or degarelix in patients with biochemically recurrent metastatic
castrate sensitive disease after radical prostectomy
CT-011 Anti-PD-1 antibody Phase II study with cyclophosphamide for advanced prostate cancer
OX40 antibody Phase I/II trial for patients with metastatic prostate cancer who have failed
prior ADT+docetaxel
Lirilumab Anti-KIR antibody Phase I trial in combination with nivolumab (anti-PD-1) in advanced solid
tumors
MSB0010718C Anti-PD-1 Phase I trial in patients with solid tumors
Adoptive cell therapy Description Status
T cells genetically engineered
to target cancer specific
antigen NY-ESO-1
Phase II trail following preparative chemotherapy regimen
T cells genetically engineered
to target cancer specific
antigen NY-ESO-1
Phase II study in combination with dendritic cell based vaccine also using
NY-ESO-1
Monoclonal antibodies Description Status
Rituximab Monoclonal antibody targeting
CD20
Phase 0 trial as neoadjuvant therapy in patients scheduled to undergo
radical prostatectomy
these cells via different approaches, including therapeutic vac-
cines, checkpoint inhibitors/immune modulators, adoptive T-cell
therapy, and monoclonal antibodies. In theory, PCa should be
particularly conducive to this type of treatment due to its long
latency period. However, because PCa is commonly diagnosed
late in life, therapeutic vaccines may not be as efficacious as
desired due to the age-related decline in immune responsive-
ness. Despite this fact, Sipuleucel-T was the first immunotherapy
approved by the FDA for PCa and has shown an overall survival
advantage in mCRPC patients, although no effect on progression-
free survival was noted (72). The lack of short-term response
observed in this study may at least partially be partially attributed
to the fact that immunotherapeutic agents are not directly cyto-
toxic, as are more standard treatments. Due to space limitations,
individual studies will not be discussed in detail here but are
summarized in Table 2 (2, 72–77). One important message from
the combined studies is that, while extremely promising, these
immunotherapeutic methodologies still need to be optimized as
no individual treatment has yet elicited a complete response.
Complete and durable responses will likely require combinations
of current immunotherapy and/or more standard approaches,
such as chemotherapy, radiation, or ADT, which induce an
immunogenic stimulus or enhance T-cell responses. In addi-
tion, ideal target patient populations and treatment protocols still
need to be identified. For example, a study combining PROST-
VAC and ipilimumab discovered that patients with lower PD-
1+Tim-3NEGCD4EM, higher PD-1NEGTim-3+CD8+, and more
CTLA-4NEG Treg at baseline survived longer. Furthermore, an
increase in Tim-3+ natural killer cells following vaccination
conferred survival benefits (78). Similarly, Klyushnenkova et al.
(79) illustrated the importance of breaking immunological toler-
ance to “self ” antigen by targeting CD25+ Treg during CTLA-4
blockade in mice. Although this research has several short-
comings, it highlights the potential value of such combination
therapies.
Summary
The presence of inflammatory cells in the prostate is well
documented. Evidence suggests that these cells may drive
PCa development. Additionally, growing tumors can induce
recruitment of immune cells into the prostate microenvironment
and initiate a reciprocal interaction that promotes disease
progression. Surprisingly, information regarding precise
profiles of prostate tumor-infiltrating leukocytes is extremely
limited. Individual cells and the overall immune response
have the potential to be anti- or pro-tumorigenic, depending
on cellular phenotypes, combinations, localization and the
tumor microenvironment. Thus, the identities, traits, functional
status, distribution, kinetics, and interactions of inflammatory
cells in the prostate and PCa must be fully characterized in
order to elevate and combine the already promising current
immunotherapies. Furthermore, efforts must be directed at
elucidating better indicators of potential response to facilitate
identification of ideal target populations, as well as biomarkers to
assess therapeutic efficacy. Progress in these areas will strengthen
the existing optimism that immunotherapy will become part of a
successful standard care regimen for future PCa patients.
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